CRL
Charles River Laboratories
Charles River Laboratories historical holders
total: 7
Ariel Appreciation Fund Charles River Laboratories transactions over time
- Total transactions:
- 21
- New positions:
- 1
- Added:
- 9
- Reduced:
- 11
- Held since:
- 2019 Q3
- Held for:
- 27 quarters
- Latest activity:
- 2026 Q1
John W. Rogers Jr. has been an institutional investor in Charles River Laboratories (CRL) since 2019 Q3. According to 2026 Q1 report, John W. Rogers Jr. holds 171,201 shares with a market value of roughly $29.53M representing 3.38% of their equity portfolio. The fund/company first acquired CRL in 2019 Q3, initially purchasing 167,680 shares. Since the initial investment, Ariel Appreciation Fund has made 20 more transactions in this position.
Does John W. Rogers Jr. still hold CRL?
Yes, John W. Rogers Jr. continues to hold Charles River Laboratories (CRL). According to their 2026 Q1 report, they maintain a position of 171,201 shares valued at approximately $29.53M, representing 3.38% of their equity portfolio.
When did John W. Rogers Jr. first invest in CRL?
John W. Rogers Jr. first invested in Charles River Laboratories (CRL) in 2019 Q3 at the reported quarter-end price of $132.37 per share, acquiring 167,680 shares in their initial purchase.
What is John W. Rogers Jr.'s average cost basis for CRL?
Based on historical transaction data, John W. Rogers Jr.'s estimated cost basis for Charles River Laboratories (CRL) is approximately $165.86 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $165.86
- Weighted AVG sell price:
- $195.06
CRL transactions history by Ariel Appreciation Fund
21 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
3.38%
|
171,201
|
$172.50
|
$29,532,172
|
-11.21% (-21,623)
|
-0.42%
|
|
2025 Q4
|
4.32%
|
192,824
|
$199.48
|
$38,464,532
|
+1.79% (+3,388)
|
+0.08%
|
|
2025 Q3
|
3.31%
|
189,436
|
$156.46
|
$29,639,157
|
+3.33% (+6,099)
|
+0.11%
|
|
2025 Q2
|
3.28%
|
183,337
|
$151.73
|
$27,817,723
|
+32.31% (+44,766)
|
+0.8%
|
|
2025 Q1
|
2.45%
|
138,571
|
$150.52
|
$20,857,707
|
-6.97% (-10,379)
|
-0.16%
|
|
2024 Q4
|
2.88%
|
148,950
|
$184.60
|
$27,496,170
|
+3.21% (+4,629)
|
+0.09%
|
|
2024 Q1
|
3.64%
|
144,321
|
$270.95
|
$39,103,775
|
-5.72% (-8,751)
|
-0.22%
|
|
2023 Q4
|
3.38%
|
153,072
|
$236.40
|
$36,186,221
|
-9.19% (-15,488)
|
-0.36%
|
|
2023 Q2
|
3.19%
|
168,560
|
$210.25
|
$35,439,740
|
+13.11% (+19,533)
|
+0.37%
|
|
2023 Q1
|
2.62%
|
149,027
|
$201.82
|
$30,076,629
|
+23.28% (+28,140)
|
+0.49%
|
|
2022 Q3
|
2.34%
|
$196.80
|
+8.98% (+9,964)
|
|||
|
2022 Q2
|
2.16%
|
$213.97
|
+105.35% (+56,907)
|
|||
|
2022 Q1
|
1.19%
|
$283.97
|
+22.66% (+9,979)
|
|||
|
2021 Q4
|
1.18%
|
$376.78
|
-7.23% (-3,431)
|
|||
|
2021 Q3
|
1.43%
|
$412.67
|
-19.52% (-11,512)
|
|||
|
2021 Q1
|
1.27%
|
$289.83
|
-8.10% (-5,200)
|
|||
|
2020 Q4
|
1.36%
|
$249.86
|
-20.45% (-16,500)
|
|||
|
2020 Q2
|
1.47%
|
$174.35
|
-20.02% (-20,200)
|
|||
|
2020 Q1
|
1.50%
|
$126.21
|
-37.91% (-61,600)
|
|||
|
2019 Q4
|
1.89%
|
$152.76
|
-3.10% (-5,200)
|
|||
|
2019 Q3
|
1.72%
|
$132.37
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.